You Position: Home > Paper
Optimizing outcome for patients with mantle cell lymphoma
( views:459, downloads:309 )
- Author:
- No author available
- Journal Title:
- Journal of Leukemia & Lymphoma
- Issue:
- 7
- DOI:
- 10.3760/cma.j.issn.1009-9921.2012.07.001
- Key Word:
- 淋巴瘤,膜细胞;靶向治疗;抗肿瘤新药;Lymphoma,mantle-cell;Targeted therapy;Antitumor drugs
Abstract： Intensive multidrug regimens,such as rituximah plus fractionated cyclophsphamide,vincristine,doxorubicin,and dexamethasone(R-HyperCVAD),are now being used to improve outcomes in patients with mantle cell lymphoma(MCL).In addition to these combinations,novel targeted agents,including bortezomib,bendamustine,and lenalidomide,are also being integrated into the treatment paradigm.Given the wide array of therapies available,making and implementing treatment decisions has become a complex process,requiring interdisciplinary collaboration.This article discussesed the pharmacist's role in this collaboration,as well as the administration of standard and novel therapies for MCL and the management of treatment related toxicities.
- [1]Lohri A,Martinelli G,Wernli M,etc.Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group fo[J].2005,16(10).
- [2]Long WL,Eickhoff JC,McFarland TA,etc.Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network.[J].2011,52(9).
- [3]Greenberg D,Zook J,Mehta J,etc.Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies.[J].2011,46(6).
- [4]Freireich EJ,O'Brien S,Pierce S,etc.Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.[J].2000,18(3).
- [5]Palumbo,A.,Cavo,M.,Bringhen,S.,etc.Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: A phase III, open-label, randomized trial[J].2011,29(8).
- [6]Robinson KS,Herst JA,Williams ME,etc.Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.[J].2008,26(27).
- [7]Chow KU,Seipelt G,Rummel MJ,etc.Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.[J].2002,87(1).
- [8]Welslau M,Rost A,Hecker R,etc.Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma.[J].2005,23(15).
- [9]Grosicki S,Cavet J,Pylypenko H,etc.Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.[J].2011,12(5).
- [10]Turner JH,Leahy MF.Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients.[J].2011,117(1).
- [11]N L,Berinstein,A J,Grillo-López,C A,White,etc.Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma.[J].1998,9(9).
- [12]Rezazedeh H,Longo WL,Eickhoff JC,etc.Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network.[J].2006,17(9).
- [13]Altman A,Pui CH,Younes A,etc.Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review.[J].2008,26(16).
- [14]Belch A,Weber D,Dimopoulos MA,etc.Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.[J].2008,22(2).
- [15]Fung HC,Yamauchi D,Falk P,etc.Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.[J].2008,26(1).
- [16]Kakkar A,Jahanzeb M,Raskob G,etc.American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.[J].2007,25(34).
- [17]Pusateri A,Gordan LN,Mendenhall NP,etc.Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders.[J].2005,23(6).
- [18]Sarris AH,Younes A,Pro B,etc.High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.[J].2005,23(28).
- [19]Najarian K,Jagannath S,Siegel DS,etc.Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.[J].2006,24(19).